17β-Estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult

Brain Research

Volumn 1164, Issue 1, 2007, Pages 24-31

  Tripanichkul, Wanida ^a   Sripanichkulchai, Kittisak ^b   Duce, James A ^c   Finkelstein, David I ^c  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

17 Estradiol; MPTP; Oxidative stress; SOD1; SOD2; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; COPPER ZINC SUPEROXIDE DISMUTASE; ESTRADIOL; MANGANESE SUPEROXIDE DISMUTASE; 3-NITROTYROSINE; BIOLOGICAL MARKER; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; SUPEROXIDE DISMUTASE; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GLIA CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; DRUG EFFECT; ENZYMOLOGY; GLIA; METABOLISM; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; UPREGULATION;

ANIMALIA; MUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BIOLOGICAL MARKERS; CELL COUNT; ESTRADIOL; MALE; MICE; MICE, INBRED C57BL; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; TYROSINE; UP-REGULATION;

EID: 34547590252     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.05.076     Document Type: Article

References (68)

1. Acarin L., Peluffo H., Barbeito L., Castellano B., and Gonzalez B. Astroglial nitration after postnatal excitotoxic damage: correlation with nitric oxide sources, cytoskeletal, apoptotic and antioxidant proteins. J. Neurotrauma 22 (2005) 189-200
2. Andreassen O.A., Ferrante R.J., Dedeoglu A., Albers D.W., Klivenyi P., Carlson E.J., Epstein C.J., and Beal M.F. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp. Neurol. 167 (2001) 189-195
3. Bannister J.V., and Calabrese L. Assays for superoxide dismutase. Methods Biochem. Anal. 32 (1987) 279-312
4. Behl C., Skutella T., Lezoualc'h F., Post A., Widmann M., Newton C.J., and Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharmacol. 51 (1997) 535-541
5. Benedetti M.D., Maraganore D.M., Bower J.H., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., and Rocca W.A. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov. Disord. 16 (2001) 830-837
6. Ben-Shachar D., Riederer P., and Youdim M.B. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57 (1991) 1609-1614
7. Biewenga E., Cabell L., and Audesirk T. Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress. Neurosci. Lett. 373 (2005) 179-183
8. Bray R.C., Cockle S.A., Fielden E.M., Roberts P.B., Rotilio G., and Calabrese L. Reduction and inactivation of superoxide dismutase by hydrogen peroxide. Biochem. J. 139 (1974) 43-48
9. Bruce-Keller A.J., Keeling J.L., Keller J.N., Huang F.F., Camondola S., and Mattson M.P. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 141 (2000) 3646-3656
10. Callier S., Morissette M., Grandbois M., Pelaprat D., and Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41 (2001) 131-138
11. Chen Y., Chan P.H., and Swanson R.A. Astrocytes overexpressing Cu,Zn superoxide dismutase have increased resistance to oxidative injury. Glia 33 (2001) 343-347
12. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., and Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 61 (2004) 886-888
13. Datla K.P., Murray H.E., Pillai A.V., Gillies G.E., and Dexter D.T. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. NeuroReport 14 (2003) 47-50
14. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., and Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989) 381-389
15. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., and Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52 (1989) 1830-1836
16. Diamond S.G., Markham C.H., Hoehn M.M., McDowell F.H., and Muenter M.D. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 40 (1990) 763-766
17. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 767 (1997) 340-344
18. Dluzen D.E., McDermott J.L., and Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/Bl mice. Neurotoxicol. Teratol. 18 (1996) 603-606
19. Dluzen D.E., McDermott J.L., and Anderson L.I. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotox. Res. 3 (2001) 291-300
20. Dringen R., Kussmaul L., Gutterer J.M., Hirrlinger J., and Hamprecht B. The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. J. Neurochem. 72 (1999) 2523-2530
21. Florian M., Freiman A., and Magder S. Treatment with 17-beta-estradiol reduces superoxide production in aorta of ovariectomized rats. Steroids 69 (2004) 779-787
22. Franklin K.B.J., and Paxinos G. The Mouse Brain in the Stereotaxic Coordinates (1997), Academic Press, San Diego
23. Garcia-Ovejero D., Azcoitia I., Doncarlos L.L., Melcangi R.C., and Garcia-Segura L.M. Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones. Brain Res. Brain Res. Rev. 48 (2005) 273-286
24. Garcia-Segura L.M., Azcoitia I., and DonCarlos L.L. Neuroprotection by estradiol. Prog. Neurobiol. 63 (2001) 29-60
25. Good P.F., Olanow C.W., and Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593 (1992) 343-346
26. Gorg B., Bidmon H.J., Keitel V., Foster N., Goerlich R., Schliess F., and Haussinger D. Inflammatory cytokines induce protein tyrosine nitration in rat astrocytes. Arch. Biochem. Biophys. 449 (2006) 104-114
27. Grandbois M., Morissette M., Callier S., and Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. NeuroReport 11 (2000) 343-346
28. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., et al. The new stereological tools: dissector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96 (1988) 857-881
29. Himeda T., Kadoguchi N., Kamiyama Y., Kato H., Maegawa H., and Araki T. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity. Neuropharmacology 50 (2006) 329-344
30. Hung H.C., and Lee E.H. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radical Biol. Med. 24 (1998) 76-84
31. Ischiropoulos H., and Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J. Clin. Invest. 111 (2003) 163-169
32. Iravani M.M., Leung C.C., Sadeghian M., Haddon C.O., Rose S., and Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur. J. Neurosci. 22 (2005) 317-330
33. Khaldy H., Escames G., Leon J., Vives F., Luna J.D., and Acuna-Castroviejo D. Comparative effects of melatonin, l-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J. Pineal Res. 29 (2000) 100-107
34. Klivenyi P., St Clair D., Wermer M., Yen H.C., Oberley T., Yang L., and Flint Beal M. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol. Dis. 5 (1998) 253-258
35. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998) 167-180
36. Kunikowska G., and Jenner P. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase. Brain Res. 922 (2001) 51-64
37. Kunikowska G., and Jenner P. The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia. Biochem. Pharmacol. 63 (2002) 1159-1164
38. Kurtzke J.F., and Goldberg I.D. Parkinsonism death rates by race, sex, and geography. Neurology 38 (1988) 1558-1561
39. Kusunoki T., Shiraishi H., and Murata K. The role of estrogen and Cu, Zn-SOD on histological changes after menopause in female rat parotid. Auris, Nasus, Larynx 33 (2006) 47-51
40. Leranth C., Roth R.H., Elsworth J.D., Naftolin F., Horvath T.L., and Redmond Jr. D.E. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J. Neurosci. 20 (2000) 8604-8609
41. Lipton S.A., Choi Y.B., Pan Z.H., Lei S.Z., Chen H.S., Sucher N.J., Loscalzo J., Singel D.J., and Stamler J.S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364 (1993) 626-632
42. McGeer P.L., Itagaki S., Akiyama H., and McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24 (1988) 574-576
43. Murray H.E., Pillai A.V., McArthur S.R., Razvi N., Datla K.P., Dexter D.T., and Gillies G.E. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 116 (2003) 213-222
44. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
45. Noack H., Lindenau J., Rothe F., Asayama K., and Wolf G. Differential expression of superoxide dismutase isoforms in neuronal and glial compartments in the course of excitotoxically mediated neurodegeneration: relation to oxidative and nitrergic stress. Glia 23 (1998) 285-297
46. Okado-Matsumoto A., and Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J. Biol. Chem. 276 (2001) 38388-38393
47. Perry T.L., Godin D.V., and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 33 (1982) 305-310
48. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., and Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12 (1992) 1658-1667
49. Qi X., Guy J., Nick H., Valentine J., and Rao N. Increase of manganese superoxide dismutase, but not of Cu/Zn-SOD, in experimental optic neuritis. Invest Ophthalmol. Visual Sci. 38 (1997) 1203-1212
50. Quesada A., and Micevych P.E. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res. 75 (2004) 107-116
51. Ramirez A.D., Liu X., and Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77 (2003) 223-231
52. Raps S.P., Lai J.C., Hertz L., and Cooper A.J. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 493 (1989) 398-401
53. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., and Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52 (1989) 515-520
54. Rosenfeld J., Cook S., and James R. Expression of superoxide dismutase following axotomy. Exp. Neurol. 147 (1997) 37-47
55. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., and Marsden C.D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53 (1989) 692-697
56. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., and Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J. Neurosci. Res. 54 (1998) 707-719
57. Shull S., Heintz N.H., Periasamy M., Manohar M., Janssen Y.M., Marsh J.P., and Mossman B.T. Differential regulation of antioxidant enzymes in response to oxidants. J. Biol. Chem. 266 (1991) 24398-24403
58. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36 (1994) 348-355
59. Slivka A., and Cohen G. Hydroxyl radical attack on dopamine. J. Biol. Chem. 260 (1985) 15466-15472
60. Strehlow K., Rotter S., Wassmann S., Adam O., Grohe C., Laufs K., Bohm M., and Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ. Res. 93 (2003) 170-177
61. Tieu K., Ischiropoulos H., and Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 55 (2003) 329-335
62. Tripanichkul W., Sripanichkulchai K., and Finkelstein D.I. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Brain Res. 1084 (2006) 28-37
63. Tsang K.L., Ho S.L., and Lo S.K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 54 (2000) 2292-2298
64. Warner D.S., Sheng H., and Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J. Exp. Biol. 207 (2004) 3221-3231
65. Wassmann K., Wassmann S., and Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ. Res. 97 (2005) 1046-1054
66. Weisiger R.A., and Fridovich I. Superoxide dismutase. Organelle specificity. J. Biol. Chem. 248 (1973) 3582-3592
67. West M.J., Ostergaard K., Andreassen O.A., and Finsen B. Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J. Comp. Neurol. 370 (1996) 11-22
68. Zhang J., Graham D.G., Montine T.J., and Ho Y.S. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol. 59 (2000) 53-61